Suniva closes $835m financing for South Carolina cell factory

Suniva has closed a US$835 million project financing for a solar cell factory in South Carolina, according to a Sept. 9 report from Renewables Now, but the available version is the outlet's standard subscription pitch, so the usable facts are the amount, the factory, and the state; no lender, coupon, or tenor appears in the material.

The sum moves this beyond an ordinary project announcement: cell manufacturing is the capital-intensive middle of the solar supply chain, and nine-figure project debt for a factory shows that transition capital is now willing to structure itself around an industrial process rather than only around generation assets. That is not the same credit: a power plant can offer a lender a long, contracted stream of cash flow, while a factory offers a construction schedule, a technology ramp, and whatever cell-price outlook its owners can assert before the plant opens.

None of that makes the deal less useful; it makes the missing terms more important, because project financing collateralizes the factory and its expected output rather than a parent balance sheet and forces borrower and lender to agree on what a cell will sell for while the debt remains outstanding. The amount says they found that agreement; the available report does not say at what price.

The opacity fits a wider pattern: thin disclosure in factory-funding announcements (Asahi Kasei's electrolyser plant financing arrived in August with terms unstated) and the spread of unpriced clean-energy milestones that PWD has previously flagged. This financing is the mirror image of that trend: the build has a price, but the product made inside the build does not.

The close demonstrates that solar cell factories can raise project debt at scale, and the next factory loan in this cycle is likely to be negotiated against this one's cost of capital. Lenders do not move this far from contracted cash flow without charging for merchant and technology risk, and that charge will set the template for the factory-financing wave. The undisclosed spread is the most consequential figure in the announcement: it is the price every future cell-plant sponsor will be measured against.